Author:
Schulthess Duane,Baird Lynn G.,Trusheim Mark,Unger Thomas F.,Lumpkin Murray,Hoos Anton,Garner Sarah,Gavin Pamela,Goldman Michel,Seigneuret Nathalie,Chlebus Magda,Van Baelen Karin,Bergstrom Richard,Hirsch Gigi
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference17 articles.
1. European Medicines Agency. European Medicines Agency launches adaptive licensing pilot project. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/03/WC500163410.pdf. Updated March 19, 2014. Accessed March 25, 2014.
2. Baird LG, Trusheim M, Eichler HG, et al. Comparison of stakeholder metrics for traditional and adaptive licensing approaches to drug development. Therap Innov Regul Sci. 2013;47;474–483.
3. Baird LG, Teagarden R., Unger T, Hirsch G. New medicines eight years faster to patients: blazing a new trail in drug development with adaptive licensing. Scrip Regulatory Affairs, May 24, 2013.
4. Schulthess D. Innovation requires a new regulatory framework to improve research and development of new medical therapies. Health Policy Technol. 2013;4:178–180.
5. Longly M, Simpson A. New medicine for serious conditions: how patients would weigh the risks and benefits. Genetic Alliance UK. 2014:28.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献